The combination of Delta-24-ACT with an anti-PD-L1 antibody extended the median survival and generated immune memory, which indicated the potential of combining immune-virotherapy with immune checkpoint inhibitors as a promising and effective strategy for the treatment of poorly infiltrated tumors such as glioma [119]. This evidence concerns the gene CD274 and glioma.